The antimicrobial resistance (AMR) infections have been on a persistence increase and thus; a worldwide public health emergency (Wright, 2013, Bennani et al., 2020). Infections that cannot be treated with leading antimicrobials with broad spectrum ability, such as the cephalosporin and uoroquinolones are huge concern, as they are multidrug-resistant infections(Woolhouse and Ward, 2013). Also, infections associated with AMR have been linked to a protracted hospital admission, thus increasing the cost of healthcare delivery (Shrestha et al., 2019). In Europe, for instance, the resistance to the use of antimicrobial agents has been associated with budgeting over nine billion Euros per year to cover the cost of health care delivery (Prestinaci et al., 2015)
Ligali, F. (2023). Microbial World (Antimicrobial Resistance in Humans) - MBI9005 - One Health. Afribary. Retrieved from https://tracking.afribary.com/works/microbial-world-one-health-folakemi-patricia-ligali
Ligali, Folakemi "Microbial World (Antimicrobial Resistance in Humans) - MBI9005 - One Health" Afribary. Afribary, 17 Aug. 2023, https://tracking.afribary.com/works/microbial-world-one-health-folakemi-patricia-ligali. Accessed 24 Nov. 2024.
Ligali, Folakemi . "Microbial World (Antimicrobial Resistance in Humans) - MBI9005 - One Health". Afribary, Afribary, 17 Aug. 2023. Web. 24 Nov. 2024. < https://tracking.afribary.com/works/microbial-world-one-health-folakemi-patricia-ligali >.
Ligali, Folakemi . "Microbial World (Antimicrobial Resistance in Humans) - MBI9005 - One Health" Afribary (2023). Accessed November 24, 2024. https://tracking.afribary.com/works/microbial-world-one-health-folakemi-patricia-ligali